DGAP-News: Alacris Theranostics ModCellTM system will use

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: Alacris Theranostics ModCellTM system will use the SAP HANA(R) platform to speed up in silico modeling of drug responses during patient treatments as well as for drug development and approval.

DGAP-News: Alacris Theranostics GmbH / Key word(s): Alliance Alacris Theranostics ModCellTM system will use the SAP HANA(R) platform to speed up in silico modeling of drug responses during patient treatments as well as for drug development and approval. 01.04.2014 / 09:30 --------------------------------------------------------------------- Press Release ______________________________________________________________ Alacris Theranostics ModCellTM system will use the SAP HANA(R) platform to speed up in silico modeling of drug responses during patient treatments as well as for drug development and approval. ______________________________________________________________ Berlin, 1st April 2014 - Alacris Theranostics has entered into a project with SAP AG (NYSE: SAP) to use the SAP HANA(R) platform to enable Alacris' proprietary ModCellTM system. This model is used for drug stratification and identification of personalized drug treatments for cancer patients. The work began through a joint project between Alacris and the SAP(R) Innovation Center in Germany. SAP will provide Alacris with SAP HANA and accessory software modules and will tailor them in collaboration with Alacris to meet the needs of ModCellTM applications. Using SAP HANA is expected to accelerate the modelling and prediction of drug action by Alacris' ModCellTM system by a factor of several thousand. This allows - in only a few minutes - to identify relevant drugs and simulate their effect on individual patients during cancer treatment, based on highly complex genome and transcriptome data. This speed-up has the potential to be a major factor in helping Alacris bring its ModCellTM applications into a broader clinical use. Moreover, by using SAP HANA Alacris expects to improve the performance of complex tasks such as simulations of single and combinatory drug action throughout the drug development and approval processes. Saving both time and computational resources for the simulations could potentially help pharmaceutical companies reach decisions sooner during drug development and approval, saving significant time and money. Through this project, Alacris will be expanding the use of SAP HANA into the field of personalized medicine and to the forefront of systems biology modeling using next-generation sequencing data. About Alacris Theranostics GmbH: Alacris Theranostics (www.alacris.de) is a company based in Berlin specialized in developing new approaches in personalized medicine for cancer patient diagnosis, treatment and drug stratification. Alacris Theranostics is applying a systems biology approach exclusively licensed as ModCellTM to Alacris. Based on genome and transcriptome information obtained by next generation sequencing and including kinetic pathway information, mutation and drug databases, the systems biology approach is providing a "Virtual Patient" model. The "Virtual Patient" model can predict the effect of drug treatment and optimized combinatory treatment providing means for truly personalized medicine approaches. In addition, Alacris' "Virtual Clinical Trials" system permits the in silico analysis of drugs, thus identifying stratified patient groups with particular genetic and molecular profiles that could be targeted by the drug, with the goal of more efficient drug development and approval. # # # SAP, SAP HANA and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries. All other product and service names mentioned are the trademarks of their respective companies. Contact: Alacris Theranostics GmbH Dr Bodo Lange, CEO Fabeckstrasse 60-62 D-14195 Berlin Germany Phone: + 49 30 8431 22 510 Email: info@alacris.de www.alacris.de MC Services AG Anne Hennecke, Managing Partner Phone +49 211 529 252 22 Email: anne.hennecke@mc-services.eu End of Corporate News --------------------------------------------------------------------- 01.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 260789 01.04.2014

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DraftKings Faces Revenue Cutback; Legal Probe Begins

Updated Category News Views 103

DraftKings' Surprising Turn of Fortune Talk about a gut punch! DraftKings (NASDAQ: DKNG) dropped a bombshell that had investors reeling. They decided to lop off a hefty slice of their revenue guidance, and trust me, those aren't small numbers we’re talking about. On November 6, they yanked their full-year 2026 revenue guidance down to $6.35 billion to $6.55 billion from...

Continue Reading
Andersen's Window Revamp: Addressing Demand Surge

Updated Category News Views 96

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Continue Reading
Tenax Therapeutics Faces Legal Heat After Stock Plunge

Updated Category News Views 92

Investors' Nerves Tested as Tenax Takes a Nosedive Holy smokes! When a biotech company like Tenax Therapeutics, Inc. (NASDAQ: TENX) detonates like a forgotten fireworks stash, investors have every right to get itchy. Tenax’s shocking announcement that their Phase 3 LEVEL trial for TNX-103 flopped has sparked more than just shareholder anxiety. It’s ignited a...

Continue Reading
212NYC Gala Celebrates Ad Industry's Human Touch

Updated Category News Views 157

The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...

Continue Reading
Pete Crow-Armstrong Unveils Signature Baseball Gloves

Updated Category News Views 83

The Windy City Meets the Diamond Alright, bear with me here. Monday morning vibes, right? But here's something that'll turn your breakfast around if you're into baseball—or just the latest scoop on players making waves in gear. Pete Crow-Armstrong, the Chicago Cubs center fielder who's been lighting up the field, has his name on some fresh gear. We're talking signature...

Continue Reading
PAC Criticizes JD Vance's Billionaire Connections

Updated Category News Views 107

Unveiling Vance's High-Powered Backers Brace yourself for a fresh round of political sparring, folks. The Patriots for American Principles PAC has decided that JD Vance's relationships with the billionaire elite need a little more sunshine. And they're not shy about it—Vance's billionaires will be paraded around the streets of Washington D.C. on a mobile billboard,...

Continue Reading
Koppers Navigates Q3: Margins Squeeze Amid Growth

Updated Category News Views 123

Investing in Koppers: A Mixed Bag in Q3 Well, it appears Koppers (NYSE: KOP) is doing a bit of a dance this quarter—some smooth steps, but a few stumbles in the rhythm when it comes to margins. The hardwood numbers tell an interesting tale, so let's break it down. Sales Edge Up, But Margins Suffer Koppers clocked in net sales of $499.1 million for the third quarter of...

Continue Reading
Precision Biologics Unveils Promising Data on PB-223

Updated Category News Views 95

Precision's Big Reveal at SITC 2026 When it comes to the shifting tides of oncology advancements, Precision Biologics is making some serious waves. They're not leaning back; they're diving right in with their latest showcase at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, 2026. CEO Dr. Philip M. Arlen announced compelling preclinical data for their...

Continue Reading
Everest Group Faces Class Action: Key Investor Moves

Updated Category News Views 117

Everest Group's Legal Spiral: What's Happening? Folks, when a company feels like it's caught in an endless storm, investors better hold on tight. That's the situation Everest Group, Ltd. finds itself in, with an 11.4% stock dive that’s got investors reeling. Securities fraud allegations are rocking Everest like a hurricane, and The Law Offices of Frank R. Cruz have put...

Continue Reading
OncoC4's Cesalatamig: Promising Results in NSCLC Trials

Updated Category News Views 85

Hope in Persistence: Cesalatamig in the Spotlight Swinging through the medical landscape like a seasoned fighter, OncoC4's recent revelations at the SITC 2026 give investors and doctors a reason to pay close attention. We're sizing up their investigational drug, cesalatamig, which flaunts a solid objective response rate of 33% among non-small cell lung cancer (NSCLC)...

Continue Reading

Top 5 Most Recently Viewed Articles

Shipley Donuts Expands to Vienna, Delight in Every Bite

Updated Category News Views 73

Shipley Donuts: A Sweet Texas Tradition Lands in Virginia The donut world just got a little tastier in Northern Virginia as Shipley Donuts, that iconic Texan sweetheart, opened shop in Vienna. We're talking handmade donuts, done the old-school way, with a taste that makes you wanna grab a dozen before work. They’ve been crafting this magic for nearly a century, starting...

Continue Reading
Volato's Strategic Expansion with Gulfstream G280 Deliveries

Updated Category News Views 224

Volato's Exciting Addition to Its Fleet Volato Group, Inc. (the "Company" or "Volato") (NYSE American: SOAR), a frontrunner in private aviation, is thrilled to announce a significant milestone: the delivery of its second Gulfstream G280 is set for January 2025. This delivery is part of a strategic order of four aircraft and underscores the company’s proactive approach...

Continue Reading
Velico's Partnership with South Texas Blood Center Revolutionizes Plasma Access

Updated Category News Views 355

Transforming Plasma Access with Innovative Technology In a historic move, the South Texas Blood and Tissue Center (STBT) has become the first civilian blood center in the U.S. to adopt Velico, Inc.'s revolutionary FrontlineODP™ system. This groundbreaking partnership aims to enhance emergency medical practices by providing on-demand spray-dried plasma, making...

Continue Reading
The Incredible Growth of Teradyne: A Decade of Investment

Updated Category News Views 119

Investing in Teradyne: A Decade of Incredible Returns When it comes to long-term investments, certain stocks have consistently proven their worth. Teradyne (NASDAQ: TER) is one such company that has outperformed market expectations over the past decade. With an impressive annualized performance exceeding 11.62%, Teradyne has become a staple in many investors' portfolios....

Continue Reading
Grid Battery Metals Expands Copper Portfolio for Future Growth

Updated Category News Views 126

Grid Battery Metals' Exciting New Copper Acquisition Grid Battery Metals Inc. has made a significant move by acquiring a new copper project, broadening its portfolio in the battery metals sector. Tim Fernback, the President and CEO, articulated the strategic importance of this acquisition and its implications for future exploration activities. Strategic Location of the...

Continue Reading